Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.
|Bidragets oversatte titel||Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine|
|Tidsskrift||Ugeskrift for laeger|
|Status||Udgivet - 8 feb. 2021|
- Antimetabolites, Antineoplastic/therapeutic use
- Dihydropyrimidine Dehydrogenase Deficiency/drug therapy
- Dihydrouracil Dehydrogenase (NADP)/genetics
- Fluorouracil/adverse effects